Introduction
============

Over the past several decades, advances in genomic sequencing technology and findings from large-scale consortia have facilitated our understanding of the complexity and flexibility of mammalian genomes. The majority of mammalian genomes are transcribed, whereas only a few transcripts encode proteins, the majority of transcripts are non-coding RNAs (ncRNAs) ([@B94]). Based on the length of transcripts, ncRNAs are usually classified into two categories: small non-coding RNAs and long non-coding RNAs (lncRNAs). Small ncRNAs are usually \<200 nucleotides, including microRNAs, Piwi-interacting RNAs and small nuclear RNAs (snoRNAs). lncRNAs are \>200 nucleotides and frequently transcribed by polymerase II, and share some features, e.g., 5′-capping, 3′-polyadenylation, alternative splicing and sequence conservation with mRNA ([@B89]; [@B77]).

Although lncRNAs generally lack protein coding capacity, spatiotemporal-specific expression patterns have highlighted the diverse functions and complicated mechanisms of lncRNAs ([@B14]). Currently, it is widely accepted that lncRNAs play an important function in a variety of biological processes, including regulating gene expression, both at the transcriptional and the post-transcriptional level, shaping the chromatin conformation and imprinting the genomic loci ([@B59]; [@B21]; [@B14]), and multiple diseases such as neurological disorders, cancer, and immunological diseases ([@B7]; [@B46]; [@B112]). In this review, we summarize the recent progress made regarding the functions of lncRNAs, especially the functions and associated mechanisms related to neurological disorders.

Characterization of LncRNA
==========================

LncRNAs are generally transcribed from various genomic contexts and tend to have fewer exons than protein-coding transcripts ([@B48]). Although there are still many challenges in annotation and interpretation of lncRNAs, because of the lack of an unambiguous classification framework, the existing lncRNAs can be subdivided into several categories based on their positional relation to protein coding genes, DNA elements or diverse mechanisms of processing ([@B103]; [@B55]) (Figure [1](#F1){ref-type="fig"}).

![Graphic illustration of the classification of lncRNAs in mammalian. General classification of lncRNAs. eRNAs, enhancer RNAs; PROMPTs, promoter upstream transcripts; lincRNAs, large intergenic ncRNAs; vlincRNA, very long intergenic ncRNAs; TIN, totally intronic long non-coding RNAs; sno-lncRNAs, small nucleolar RNA (snoRNA)-ended lncRNAs; NATs, natural antisense transcripts; PIN, partially intronic lncRNAs; ciRNAs, circular intronic RNAs; circRNAs, circular RNAs; TERRA, telomeric repeat-containing RNA.](fgene-09-00744-g001){#F1}

Sense lncRNAs are transcribed from the sense DNA strand, and have overlapping regions with protein-coding genes, including un-spliced sense partially intronic RNAs (PINs) and spliced transcripts resembling mRNAs ([@B103]). Further, natural antisense transcripts (NATs) of protein-coding genes have also been identified and many NATs share some opposite strand DNA sequences with the sense transcripts ([@B51]). Some studies also indicate that NATs have either positive or negative effects on the corresponding sense transcripts or nearby protein-coding transcripts ([@B34]; [@B75]). For example, human brain-derived neurotrophic factor antisense RNA (*BDNF-AS*) was originally identified as natural antisense transcripts of neuronal transcriptional factor BDNF, shares 225 complementary nucleotides with BDNF mRNA and regulates the expression of BDNF both *in vivo* and *in vitro* ([@B75];[@B36]).

Other studies indicate that intronic regions of coding genes produce a lot of lncRNAs. These intronic lncRNAs form the largest class of lncRNAs and are expressed independently from the pre-mRNA of protein coding genes. Many intronic lncRNAs fail to be debranched after splicing and form a covalent circle without 3′ linear appendages, these circular intronic ncRNAs (ciRNAs) were found to play a regulatory role on their host genes ([@B132]). In addition, circRNAs derived from the internal exons of pre-mRNAs through back-splicing, have also been found in various cell lines and tissues ([@B122]). These circular ncRNAs usually present tissue- and developmental stage-specific expression, such as the intensively studied cerebellar degeneration-related protein 1(CDR1as) ([@B73]).

A relatively well-characterized subclass of lncRNAs is large/long intergenic or intervening non-coding RNAs (lincRNAs), and transcribed from the intergenic regions. LincRNAs have no overlapping sequences with transcripts of either protein-coding genes or other types of genes ([@B26]). At the molecular level, most annotated lincRNAs have mRNA-like features including 5′-cap structures, 3′-poly(A) tails, exon--exon splice junctions and association with ribosomes ([@B10]). Compared with mRNA counterparts, lincRNAs exhibit a more tissue-specific expression, a greater nuclear localization and less evolutionary conservation ([@B31]).

Promoter upstream transcripts (PROMPTs) localize in a fairly narrow region between ∼500 and ∼2500 nucleotides upstream of transcription start sites of nearby active protein-coding genes ([@B90]; [@B69]). It was reported that the expression levels of certain PROMPTs are altered in stress conditions, such as DNA damage responses and osmotic responses ([@B69]; [@B102]). Enhancer-related lncRNAs (eRNAs) are bidirectional transcripts of enhancers and have enhancer-like functions. Increased binding of DNA hydroxylase Tet1 and histone methyltransferases Mll3/Mll4 and DNA hypomethylation and H3K27ac modifications at enhancers, may activate eRNAs transcription. Both PROMPTs and eRNAs are targets of the RNA exosome and display similarities during processing ([@B1]; [@B122]).

Emerging evidence indicates that telomeric repeat-containing RNA (TERRA) is a heterogeneous lncRNA consisting of a combination of subtelomeric and telomeric sequences. These sequences are mostly transcribed from intrachromosomal telomeric repeats by pol II and polyadenylated at 3′ region ([@B71]). The length and expression level of human TERRA is influenced by the telomere length. The vast majority of mouse TERRA-binding sites were found in distal intergenic and intronic regions, where TERRA may regulate expression of target genes ([@B25]; [@B29]).

SnoRNA-ended lncRNAs (sno-lncRNAs) are transcripts of one intron flanked by two snoRNA genes that can be further processed to form snoRNA. sno-lncRNAs can be stabilized by snoRNPs formed by snoRNAs and specific protein components. *SLERT* is a representative Box H/ACA snoRNA-ended lncRNA and has been reported to be translocated to the nucleus by snoRNAs to function in pre-rRNA biogenesis ([@B122]).

Physiological Functions of LncRNA
=================================

Loss- and gain-of-function studies revealed that many lncRNAs are involved in various biological processes during development. Many lncRNAs have been found to regulate transcription via chromatin modulation, by working as molecular scaffolds for protein--protein interactions or interacting with chromatin modifying complexes and recruiting chromatin modifying complexes to specific loci, to activate or repress target gene expression. Some lncRNAs could affect transcription by modulating the binding of the general transcription machinery and regulatory factors ([@B113]; [@B35]; [@B112]; [@B61]). Aside from modulating chromatin states, nuclear lncRNAs are involved in the RNA processing ([@B109]), turnover, silencing, translation and decay of mRNAs ([@B40]; [@B15]; [@B37]), or act as miRNA decoys to neutralize miRNA-mediated mRNAs silencing and interact with signaling molecules, to modulate signaling pathways ([@B34]; [@B67]). In addition, some lncRNAs are determined to be precursors of certain miRNAs at particular stages of development ([@B32]) (Table [1](#T1){ref-type="table"}).

###### 

Diverse mechanisms of lncRNAs playing function.

  Mechanism                         lncRNA        Function                                                       Relationship with target (*Cis/Trans*)   Reference
  --------------------------------- ------------- -------------------------------------------------------------- ---------------------------------------- -----------------
  Chromatin remodeling              ANRIL         Repression at the CDKN2A/B locus                               *Cis/trans*                              [@B28]
                                    BCAR4         SNIP1 and PNUTS recruitment                                    *Trans*                                  [@B125]
                                    Braveheart    Activation of *MesP1*                                          *Trans*                                  [@B54]
                                    cga eRNA      Formation of looping between enhancer and promoter             *Cis*                                    [@B88]
                                    COOLAIR       Repression at the FLC locus                                    *Cis*                                    [@B72]
                                    FENDRR        PRC2 and TrxG/MLL complexes recruitment                        *Trans*                                  [@B41]
                                    H19           Genomic imprinting                                             *Cis/trans*                              [@B12]
                                    HAUNT         Repression at the HOXA locus                                   *Cis*                                    [@B128]
                                    HOTAIR        Repression at the HOXD locus                                   *Trans*                                  [@B11]
                                    HOTTIP        Activation at the HOXA locus                                   *Cis*                                    [@B65]
                                    HOXD-AS1      Recruitment of WDR5 to target genes                            *Trans*                                  [@B42]
                                    Kcnq1ot1      Imprinting at the KCNQ1 cluster                                *Cis*                                    [@B24]
                                    lncTCF7       Recruitment of SWI/SNF complex to TCF7                         *Cis*                                    [@B120]
                                    MEG3          Accumulation of p53 protein                                    *Cis/trans*                              [@B136]
                                    Oct4P4        Repression at the Oct4 locus                                   *Trans*                                  [@B97]
                                    PAPAS         rRNA synthesis                                                 *Cis*                                    [@B134]
                                    PARTICLE      Repression of methionine adenosyltransferase 2A                *Cis/trans*                              [@B84]
                                    TERRA         Felomeric heterochromatin formation                            *Cis/trans*                              [@B71]
                                    TSIX          X inactivation                                                 *Cis*                                    [@B95]
                                    XIST          X inactivation                                                 *Cis*                                    [@B18]
                                    Six3OS        Recruit histone modification enzymes to Six3 target genes      *Trans*                                  [@B93]
  DNA methylation                   APTR          Recruitment of PRC2 to CDKN1A/p21                              *Trans*                                  [@B79]
                                    DALI          DNA methylation on promoter regions of target genes            *Trans*                                  [@B19]
                                    DUM           DNA methylation on Dppa2                                       *Cis*                                    [@B114]
                                    Evf2/Dlx6as   Transcriptional repression of Evf2 and Dlx5                    *Cis/trans*                              [@B4]
                                    FIRRE         H3K27me3 methylation maintenance                               *Trans*                                  [@B126]
  miRNA binding                     CDR1as        miR-7 decoy                                                    *Trans*                                  [@B131]
                                    lincRNA-ROR   miR-145 binding                                                *Trans*                                  [@B118]
                                    lncRNA-ATB    miR-200s binding                                               *Trans*                                  [@B63]
                                    UCA1          miR-184 sponge                                                 *NA*                                     [@B62]
                                    TUG1          miR-144/145 binding                                            *Trans*                                  [@B64]
  Transcriptional regulation        Uph           Repression at the *Hand2* locus                                *Cis*                                    [@B55]
                                    Paupar        Negative regulation Pax6 expression                            *Cis/trans*                              [@B111]
                                    PANDA         Repression of NF-YA-mediated transcription                     *NA*                                     [@B91]
                                    Airn          Imprinting at the IGF2R cluster                                *Cis*                                    [@B55]
                                    RMST          Transcriptional coregulator of SOX2                            *Trans*                                  [@B80].
  Post transcriptional regulation   MALAT1        Ser/Arg splicing factor regulation                             *Trans*                                  [@B123]
                                    PCA3          PRUNE2 editing and stability                                   *Cis*                                    [@B96]
                                    CCAT2         Alternative splicing of Glutaminase (GLS)                      *Trans*                                  [@B124]
                                    MIAT          Alternative splicing of DISC1, ERBB4                           *Trans*                                  [@B104]
                                    Sirt1 AS      Promotion of *Sirt1* mRNA stability                            *Cis*                                    [@B117]
                                    TINCR         Stability of multiple mRNAs                                    *Trans*                                  [@B57]
                                    1/2-sbsRNA    Activation of STAU1-mediated decay                             *Trans*                                  [@B40]
                                    BACE1-AS      Positive regulation of BACE1                                   *Cis*                                    [@B76]
                                    aHIF          Nuclear membrane trafficking                                   *Cis*                                    [@B17]
                                    AS UCHL1      UCHL1 mRNA translation                                         *Cis*                                    [@B16]
                                    lincRNA-p21   Translational suppression                                      *Cis*                                    [@B30]
                                    ZEB2 NAT      Activation of ZEB2 translation                                 *Cis*                                    [@B5]
                                    NORAD         Inhibition of PUM protein activity                             *NA*                                     [@B60]
                                    SNHG4/5/6     Localization of MTA2 protein in the nuclear                    *NA*                                     [@B20]; [@B135]
                                    LINK-A        Recruitment of BRK to GPNMB                                    *NA*                                     [@B121]
                                    NEAT1         Formation of nuclear paraspeckles                              *Trans*                                  [@B27]
                                    AOC4P         Degradation of vimentin                                        *Trans*                                  [@B115]
                                    ASBEL         Localization of ANA/BTG3 mRNA in the nuclear                   *Cis*                                    [@B133]
                                    GAS5          Repression of glucocorticoid receptor-mediated transcription   *NA*                                     [@B53]
                                                                                                                                                          

LncRNAs and Stem Cell Pluripotency and Differentiation
------------------------------------------------------

Accumulating evidence suggests that lncRNAs exert critical functions in pluripotency maintenance, reprogramming and lineage differentiation of stem cells ([@B113]; [@B39]). The long intergenic non-protein coding RNA regulator of reprogramming (*lincRNA-ROR*), increases the reprogramming efficiency of human induced pluripotent stem cells (iPSCs) and promotes the maintenance of embryonic stem cells (ESCs) pluripotency ([@B70]). Similar to a miRNA sponge, *lincRNA-ROR* forms a regulatory feedback loop with miR-145 and OCT4, SOX2, and NANOG, and regulates ESC pluripotency ([@B118]). *MIAT* (myocardial infarction associated transcript) is a co-activator of Oct4 and participates in OCT4 and NANOG regulatory networks in mouse ESCs. Loss of *MIAT* reduces the expression of *Oct4, Sox2*, and *Klf4*, and inhibits ESCs proliferation ([@B100]).

LncRNAs and Development
-----------------------

Genomic imprinting is an important epigenetic mechanism and is crucial for normal development in mammals. It restricts gene expression on one of the two parental chromosomes in diploid cells and affects both male and female descendants ([@B2]). *H19*, a maternally expressed 2.3 kb lncRNA, is generated from the highly conserved and imprinted vertebrate gene cluster insulin-like growth factor 2 (*Igf2*)/*H19*. *H19* transcripts are the precursors of miR-675-3p and miR-675-5p ([@B12]). Before parturition, *H19* slows the growth of the placenta down partially, by down-regulating the RNA binding protein HuR. The decreased HuR cannot block the processing of miR-675, which further decreases the growth regulator *Igf1r* with *Igf2* as its main ligand ([@B52]). Another two well-characterized lncRNAs that have been found to regulate genomic imprinting are *Kcnq1ot1* (*KCNQ1* opposite strand transcript 1) and *Airn* (antisense of *IGF2R* non-protein coding RNA), both are paternally expressed and regulate transcriptional silencing through a multilayered silencing pathway ([@B87]).

Besides genomic imprinting, dosage compensation plays a vital role in equalizing the dosage of X-linked genes between males and females in heterogametic species. *Xist* is a 17 ∼ 20 kb lncRNA and transcribed from the X inactivation center. During female development, *Xist* initiates X-chromosome inactivation (XCI), by progressively coating the future inactive X chromosome (Xi) and then utilizing its conserved A-repeat domain to bind PRC2, to form a transcriptionally silent nuclear compartment. The compartment is enriched by H3K27me3 and responsible for the chromosome-wide gene repression in the Xi ([@B23]). *TSIX*, transcribed from the active chromosome (Xa), represses *Xist* at the early steps of X inactivation ([@B38]). Another lncRNA *JPX/ENOX*, which is transcribed from *Jpx/Enox* gene, that resides 10 kb upstream of *Xist*, also involves in XCI through repressing the *TSIX* expression from the Xi and evicting nuclear protein CCCTC-binding factor (CTCF) away from promoter of *XIST* to activate the *XIST* expression from Xi ([@B105]).

LncRNAs in Neurodevelopment
---------------------------

A great number of lncRNAs are expressed during neural development and in the brain. Using high-throughput technologies, *in situ* hybridization, microarray analysis and RNA sequencing (RNA-seq), researchers have found that most of the lncRNAs examined (849 out of 1328) are expressed in specific cell types, subcellular compartments and different regions of the brain ([@B81]; [@B101]). LncRNAs display differential expressions across the cortical layers, and region-specific expressions in the subventricular zone, dentate gyrus and olfactory bulb of mice ([@B3]; [@B92]). Based on a unique custom microarray platform, 8 lncRNAs were identified to be expressed in an age-dependent manner, from 36 surgically resected human neocortical samples, ranging from infancy to adulthood ([@B66]). However, the function of those lncRNAs need to be validated, through loss-of-function assays, RNA-protein association assays or assessments of RNA-chromatin association.

Some lncRNAs are also found to participate in neural cell fate determination, neuronal-glia fate switching and oligodendrocyte elaboration. An antisense transcript of the distal-less homeobox 1 (*Dlx1*), *Dlx1AS*, was discovered to be up-regulated during GABAergic differentiation and down-regulated during oligodendrocyte differentiation ([@B74]). A subsequent study found that *Dlx1AS* participated in neurogenesis, implying its function in neuronal differentiation by regulating expression of its homeobox gene neighbors ([@B92]). *Evf2*, a cloud-forming *Dlx5/6* ultra-conserved eRNA, influences the formation of GABAergic interneurons in both a mouse and human forebrain. In the developing ventral forebrain, *Evf2* regulates *Dlx5, Dlx6* and glutamate decarboxylase 1 (*Gad1*) expression by recruiting DLX1 and/or DLX2 and methyl CpG binding protein 2 (MeCP2) to specific DNA regulatory elements. GAD1 is an enzyme responsible for catalyzing glutamate to form GABA. *Evf2* mouse mutants reduced GABAergic interneurons in the early postnatal dentate gyrus and hippocampus ([@B9]; [@B4]; [@B13]).

The vertebrate retina is comprised of three well-organized cell type-specific neuron layers, interconnected by synapses ([@B81]). *Six3OS* is the long non-coding opposite strand transcript (lncOST) of the homeodomain factor *Six3*. During mammalian eye development, *Six3* regulates both early eye formation and postnatal retinal cell specification. Knockdown of *Six3OS* leads to a decrease of bipolar cells and an increase of Müller glia, similar to the results in the knockdown of *Six3*. In contrast, overexpression of *Six3OS* decreased syntaxin positive cells. Gene perturbation studies revealed that *Six3OS* participates in retinal cell specification as a molecular scaffold, to regulate *Six3* activity rather than expression ([@B93]). *TUG1* (taurine upregulated gene 1), a spliced and polyadenylated lncRNA, is highly conserved in humans and mice. *TUG1* may participate in rod-photoreceptor genesis and inhibits cone-photoreceptor gene expression globally, by altering the chromatin configurations of photoreceptor-specific transcription factors Crx and Nrl ([@B129]).

LncRNAs in Neurologic Disorders
===============================

Emerging evidence has shown that the dysregulation of lncRNAs is related to multiple neurological disorders, such as schizophrenia ([@B98]), autism spectrum disorder (ASD) ([@B116]), Parkinson's ([@B83]), Huntington's ([@B106]) and Alzheimer's diseases ([@B33]).

Schizophrenia (SCZ) is a debilitating mental disorder with a broad spectrum of neurocognitive impairments. Abundant data suggests that both genetic and environmental factors contribute to the pathophysiology of SCZ ([@B99]). Several lncRNAs have been used as biomarkers and therapeutic targets for SCZ ([@B22]). lncRNA *MIAT*, also known as Gomafu or RNCR2, is down-regulated in SCZ upon neuronal activation ([@B104]). Previous studies found MIAT either acts as a competitive endogenous RNA (ceRNA) for miR-150-5p, miR-24, miR-22-3p or miR-150, to influence cell proliferation, apoptosis and migration, or participates in various signaling pathways by enhancing Nrf2 (nuclear factor erythroid 2-related factor 2) and Oct4 expression. Subsequent studies revealed that *MIAT* can directly bind to the splicing regulator quaking homolog (QKI) and splicing factor 1 (SF1), to modulate several gene expressions in the neuron. In SCZ patient brains, *DISC1* (disrupted in schizophrenia 1), *ERBB4* (v-erb-a erythroblastic leukemia viral oncogene homolog 4) and their alternatively spliced variants were all down-regulated due to *MIAT* up-regulation. *MIAT* could act as a scaffold to affect alternative splicing of those SCZ-associated genes ([@B94]; [@B68]; [@B104]).

Autism spectrum disorder (ASD) is a heterogeneous group of neurodevelopmental disorders characterized by impaired reciprocal social interactions, communication, and repetitive stereotyped behaviors ([@B107]). 222 differentially expressed lncRNAs have been identified from autistic brain tissues. 90% of these lncRNAs are oriented in or around known genes related to neurodevelopmental and psychiatric diseases, such as *UBE3A* (ubiquitin protein ligase E3A), which is associated with Angelman syndrome, that shares common features with ASD. At the same time, it has been found that the number of lncRNAs differentially expressed within a control sample, was much greater than that within an autistic sample (1375 lncRNAs vs. 236 lncRNAs, respectively) ([@B137]). A genome-wide association study (GWAS) of ASD identified a 3.9 kb lncRNA designated MSNP1AS, which is encoded by the opposite strand of the moesin pseudogene 1 (*MSNP1*). The sense transcript MSN encodes the moesin protein that regulates neuronal architecture and immune responses. MSNP1AS was found to be significantly upregulated in a postmortem ASD temporal cortex, and overexpression of *MSNP1AS* led to significant decreases in MSN, moesin, neurite number and length in cultured neurons. Thus, *MSNP1AS* contributes to ASD risk, by possibly influencing the sense transcript MSN expression negatively ([@B119]).

*BACE1-AS* is a conserved non-coding antisense transcript of β-secretase 1 (*BACE1*) and has been shown to be closely associated with Alzheimer's disease (AD). BACE1 is responsible for the generation of β-amyloid and the amyloid plagues in the brain, which are the primary pathophysiology of AD. *BACE1-AS* is markedly up-regulated in AD brains and promotes the stability of BACE1 through stabilizing BACE1 mRNA, thereby increasing the BACE1 protein and Aβ1--42 levels ([@B33]). Knock down of *BACE1-AS in vivo* resulted in the down-regulation of both *BACE1* and *BACE1-AS*, along with reduced β-amyloid in the brain. In addition, the brain cytoplasmic RNA BC200 (*BCYRN1*), GDNF gene antisense transcript (*GDNF-AS*) and Sox2 overlapping transcript (*Sox2OT*), all participate in progress and development in AD brains ([@B112]).

Huntington disease (HD) is a hereditary neurodegenerative disease with symptoms including dementia, chorea, and psychiatric disturbances. HD is caused by a CAG trinucleotide abnormal expansion in the first exon of the huntingtin gene and its probability of occurrence is 1/10000. Microarray data found that the expression of four lncRNAs significantly changed in HD brains: *NEAT1* (nuclear paraspeckle assembly transcript 1) and *TUG1* are upregulated, and *DGCR5* (DiGeorge syndrome critical region gene 5) and *MEG3* (maternally expressed 3) are downregulated. The up-regulation of *NEAT1* in HD might contribute to the pathogenic alteration of the transcriptional status, by sequestrating various paraspeckle proteins ([@B106]), whereas *TUG1* is possibly activated by p53 and then interacts with PRC2, to affect downstream HD-associated genes. DGCR5 and MEG3, are both direct targets of REST. Their down-regulation may result from the aberrant accumulation of REST in the nuclei of striatal neurons in HD ([@B49]; [@B47]). Using the whole genome chromatin immunoprecipitation sequencing (ChIP-Seq) method, *HAR1*, a deeply conserved genomic region that is directly bound by REST was confirmed. This region encodes a pair of structured lncRNAs as well, HAR1F and HAR1R. Both HAR1F and HAR1R were downregulated in the striatum of HD patients ([@B50]).

Parkinson's disease (PD) is one of most prevalent neurodegenerative disorders, characterized by progressive impairments of motor abilities caused by the loss of dopamine-producing cells in the brain. Antisense ubiquitin carboxy-terminal hydrolase L1 (*AS-Uchl1*) was discovered to up-regulate the translation of *UchL1* protein at a post-transcriptional level depending on a 5′ overlapping sequence and an embedded inverted SINEB2 sequence ([@B15]). *AS-Uch1* is strongly down-regulated in neurochemical models of PD as a component of the Nurr1-dependent gene network and the subsequent reduced translation of UCHL1 protein, lead to the perturbation of the ubiquitin-proteasome system ([@B16]). *H19* upstream conserved 1 and 2 (*Huc1* and *Huc2*), *lincRNA-p21, MALAT1, SNHG1*, and *TncRNA* were differentially expressed in PD patients ([@B56]). As these lncRNAs are associated with synaptogenesis, proliferation and apoptosis, the expression of these lncRNAs precede the course of PD, suggesting they may be biomarkers of PD ([@B56]).

Mechanisms of LncRNAs in Biological Processes
=============================================

lncRNAs could provide functions through differential mechanisms, including serving as molecular scaffolds, molecular signals, guiding chromatin modifiers, and miRNA sponges, etc. (Figure [2](#F2){ref-type="fig"}).

![Graphic illustration of Mechanisms of lncRNAs playing functions. (1) lncRNAs can titrate transcription factors away from chromatin; (2) lncRNAs can serve as a scaffold to form ribonucleoprotein complexes; (3) lncRNAs can recruit chromatin-modifying enzymes to target genes; (4) lncRNAs can be precursors of small regulatory RNAs; (5--8) lncRNAs can regulate processes such as RNA splicing, translation and decay, in addition to miRNA binding; (9--11) lncRNAs can participate in protein--protein interactions, regulate protein activity and present as a structural component in the cytoplasm.](fgene-09-00744-g002){#F2}

Molecular Scaffolds
-------------------

*Xist*, a 17 ∼ 20 kb lncRNA transcribed from the X inactivation center, initiates X-chromosome inactivation (XCI) by progressively coating the future inactive X chromosome (Xi). *Xist* can bind to chromatin-modifying complexes PRC2 through the conserved A-repeat domain and form a transcriptionally silent nuclear compartment. This compartment is responsible for the chromosome-wide gene repression in the Xi ([@B23]). Another example of the lncRNA acting as a molecular scaffold is the *HOTAIR*, which are transcripts of the antisense strand of HOXC gene cluster, which can modulate nearby gene expression by interacting with PRC2 and lysine specific demethylase 1 (LSD1) ([@B110]).

lncRNA *tsRMST*, an isoform of RMST (rhabdomyosarcoma 2 associated transcript) was highly expressed in human iPSCs and ESCs. Further studies revealed that *tsRMST* down-regulation leads to NANOG and the PRC2 complex component SUZ12 fail to bind to the promoters of several inactive genes. These genes are thereby activated and promote ectoderm and endoderm differentiation ([@B82]; [@B130]).

Molecular Signals
-----------------

Genomic imprinting restricts gene expression on one of the two parental chromosomes and the parental-specific gene expression in diploid cells, and affects both male and female descendants ([@B2]). *H19* transcripts are the precursors of miR-675-3p and miR-675-5p ([@B12]). Before parturition, H19 slows the growth of the placenta down partially, through down-regulating the RNA binding protein HuR. The decreased HuR fails to block the processing of miR-675, which further decreases the growth regulator *Igf1r* ([@B52]).

*MALAT1* (metastasis-associated lung adenocarcinoma transcript (1) is initially found as an abundant lncRNA in nuclear speckles to regulate processes of mRNA alternative splicing by modulating the levels of serine/arginine splicing factors ([@B109]). Recent studies confirmed that *MALAT1* is a sensitive prognostic marker for lung cancer metastasis and linked to several other human cancers ([@B43]).

Guiding Chromatin Modifiers
---------------------------

Genome regulation via DNA methylation and post-translational histone modifications by the activity of chromatin modifiers, is a well-documented function of lncRNA in eukaryotes ([@B8]; [@B78]). Altered DNA methylation patterns at CpG islands and mutations in chromatin modifiers, may result in oncogenesis ([@B44]; [@B78]).

The first lncRNA identified to interact with both maintenance and *de novo* methylases, *Dum*, is tightly associated with myogenesis and transcriptionally induced by MyoD upon myoblast differentiation. *Dum* can recruit DNA methyltransferase1/3a/3b complex to the *Dppa2* promoter, through intra-chromosomal looping, mediated by RAD21 and NIPBL, resulting in two CpG loci hypermethylation and *Dppa2* silencing ([@B114]). Recent studies of *HOTAIR* suggest that under heypoxia, *HOTAIR* expression is up-regulated in several cancer cells induced by the hypoxia-inducible factors (HIFs), recruiting hypoxia-response elements (HRE) to bind on the *HOTAIR* promoter. Along with HIFs, histone acetyltransferase CREB-binding protein (CBP/p300) and histone H3K4 specific methyltransferases, mixed lineage leukemia (MLL) family, are enriched in the HRE region of the *HOTAIR* promoter ([@B6]).

Additionally, N-Myc can directly bind to the JMJD1A promoter to upregulate JMJD1A expression in neuroblastoma cells. The upregulated JMJD1A then directly binds to the *MALAT1* promoter to demethylate H3K9, to activate *MALAT1* expression ([@B108]; [@B86]). Furthermore, *H19* and mir-675 were found to participate in the adipogenesis through mir-675, targeting the histone deacetylase (HDAC) 4--6 3′ untranslated regions and inducing HDACs 4--6 down-regulation. The reduced HDAC 4--6 then reduced *H19* expression, possibly by reducing the levels of CTCF occupancy in the *H19* imprinting control region. H19 inhibition then facilitates the bone marrow mesenchymal stem cells differentiating into adipocytes ([@B45]).

miRNA Sponges
-------------

A handful of microRNAs have been reported to influence the mRNA stability of protein-coding genes on post-transcriptional level. Recent studies on lncRNAs discovered several miRNA-lncRNA interactions based on in *silico* and experimental analyses ([@B85]). One of the well-studied lncRNAs which act as miRNA sponges, is *lincRNA-ROR*, which decoys miR-145 in self-renewing human ESCs. A regulatory feedback loop formed by lincRNA-RoR, miR-145 and the core transcription factors OCT4, SOX2, and NANOG is closely related to the ESCs pluripotency ([@B118]). *MALAT1* not only interacts with several splicing factors, but also binds to miRNAs including miR-101, miR-9, miR-125b, and miR217 to regulate the interactions between miRNA and mRNAs ([@B85]).

Other Mechanisms
----------------

Some lncRNAs exert their function by maintaining DNA looping between enhancer and promoter regions, or by recruiting chromatin regulatory proteins to establish high affinity interactions between different regions of the DNA, resulting in closely positioned promoters and enhancers ([@B127]). For example, *linRNA-p21* regulates the expression of its neighboring gene *p21*, by *cis*-regulatory enhancer-like DNA elements, which embed within the *p21* gene body ([@B30]). lncRNAs can also interact with DNA directly through nucleic-acid hybridization, and regulate nearby gene expression, such as *Airn* (antisense of IGF2R non-protein coding RNA), which produces transcription interference on paternal allele, by spanning the *Igf2* gene promoter ([@B58]). Additionally, lncRNAs may influence the three-dimensional organization of the mammalian nucleus. *FIRRE* (firre intergenic repeating RNA element) is transcribed from the X chromosome, and interacts with hnRNPU in the process of nuclear organization ([@B126]). *Trans*-acting lncRNAs also modulate the protein activity and RNA stability by directly binding in the nucleus or cytoplasm. lncRNA NORAD functions as a negative regulator of the RNA binding protein PUMILIO1 and 2 (PUM1 and 2) in the cytoplasm. The knockdown of NORAD leads to the degradation of PUM1/2 targeted mRNAs ([@B60]).

Perspectives
============

Previous studies have revealed that lncRNAs play an important role in neuronal development and function through differential mechanisms. The dysregulation of lncRNAs could result in neurological diseases. Advances in sequencing technologies and their applications will contribute substantially to uncovering and investigating novel lncRNAs and their functions.

One challenge in the lncRNA field is whether lncRNAs can be used as diagnostic biomarkers or therapeutic targets for diseases. Considering that the down-stream targets of lncRNAs could be broad, it is hard to use it as a specific "key" to one "lock." Although the validation of their functions could be performed *in vitro* and *in vivo*, it is difficult to claim a specific target. Another challenge is to better understand the mechanisms of lncRNAs functions. It is highly necessary to develop proper genetic tools and to establish animal models to dissect the regulatory networks of lncRNAs, and their interaction with other epigenetic modifications.
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